If you are looking for ASX 200 stocks to buy in April after recent weakness, then it could be worth listening to what analysts at Bell Potter are saying.
That's because the broker has just revealed its favoured picks for the month ahead on its Australian equities panel.
The broker notes that these are the shares that it believes "offer attractive risk-adjusted returns over the long term."
Its analysts also point out that when identifying picks, it considers the current macro-economic backdrop and investment environment, focusing on quality companies with proven track records, capable management, and competitive advantages.
With that in mind, let's look at two ASX 200 stocks make the list this month. They are as follows:
Evolution Mining Ltd (ASX: EVN)
Bell Potter has added this gold miner to its Australian equities panel this month. The broker believes it could be a great way to play the sky high gold price, which it believes will be staying higher from longer.
The broker has named three key reasons why it has named it on its panel. It said:
We see the best way to currently play a higher for longer gold price is through EVN for 3 key reasons. 1. Gold price at spot is not in consensus numbers, FY26 will see large upgrades if spot stays around ~3000 us/oz as we expect. 2. EVN is a diversified across both gold and copper, we like this environment as both are currently rising. Copper can also act as a hedge against gold volatility, and 3. EVN is fundamentally strong, they have navigated their re-lake issues, delivering low AISC, have little to no hedging, past peak capex and are likely to continue to pay healthy returns to shareholders.
Telix Pharmaceuticals Ltd (ASX: TLX)
Another ASX 200 share that gets thumbs up this month is integrated radiopharmaceutical specialist company Telix. It is also a new addition to the panel in April.
The broker is feeling positive due to there being a number of catalysts on the horizon that could help drive its shares higher in the near term. It is also expecting solid earnings growth in the coming years. It explains:
Telix has built itself into a successful vertically integrated radiopharmaceutical specialist company. While TLX already has a product in market, with strong expected revenue growth, they also have 3 key catalysts on the horizon, including product launches, product approvals and interim readouts on trials. The company also has strong earnings momentum (through 3m revisions) and high earnings growth over the forward years.
